BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 36017851)

  • 1. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
    Kim IS; Yang WS; Kim CH
    Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional mimetic peptide discovery isolated by phage display interacts selectively to fibronectin domain and inhibits gelatinase.
    Shoari A; Rasaee MJ; Kanavi MR; Daraei B
    J Cell Biochem; 2019 Dec; 120(12):19699-19711. PubMed ID: 31270859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
    Das S; Amin SA; Jha T
    Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).
    Almutairi S; Kalloush HM; Manoon NA; Bardaweel SK
    Molecules; 2023 Jul; 28(14):. PubMed ID: 37513440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation.
    Reynolds JJ
    Oral Dis; 1996 Mar; 2(1):70-6. PubMed ID: 8957940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
    Liu J; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting.
    Abdel-Hamid NM; Abass SA
    Mol Biol Rep; 2021 Sep; 48(9):6525-6538. PubMed ID: 34379286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.
    Cabral-Pacheco GA; Garza-Veloz I; Castruita-De la Rosa C; Ramirez-Acuña JM; Perez-Romero BA; Guerrero-Rodriguez JF; Martinez-Avila N; Martinez-Fierro ML
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status of research on matrix metalloproteinases (MMPs) in India.
    Bulbule A; Saraswati S; Kundu GC
    Expert Opin Ther Targets; 2011 Jun; 15(6):671-5. PubMed ID: 21476880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.
    Siasos G; Tousoulis D; Kioufis S; Oikonomou E; Siasou Z; Limperi M; Papavassiliou AG; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1132-48. PubMed ID: 22519444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology.
    de Almeida LGN; Thode H; Eslambolchi Y; Chopra S; Young D; Gill S; Devel L; Dufour A
    Pharmacol Rev; 2022 Jul; 74(3):712-768. PubMed ID: 35738680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.
    Benjamin MM; Khalil RA
    Exp Suppl; 2012; 103():209-79. PubMed ID: 22642194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Implication of extracellular matrix metalloproteinases in the course of chronic inflammatory airway diseases].
    Lechapt-Zalcman E; Escudier E
    Morphologie; 2000 Jun; 84(265):45-9. PubMed ID: 11048298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
    Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
    J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases (MMPs) in health and disease: an overview.
    Malemud CJ
    Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of matrix metalloproteinases in the pathogenesis of diabetes mellitus and progression of diabetes retinopathy].
    Naduk-Kik J; Hrabec E
    Postepy Hig Med Dosw (Online); 2008 Sep; 62():442-50. PubMed ID: 18772849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in adult human sarcoma cell lines.
    Roomi MW; Kalinovsky T; Niedzwiecki A; Rath M
    Int J Oncol; 2013 Jul; 43(1):39-49. PubMed ID: 23661254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease.
    Chen Y; Peng W; Raffetto JD; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 147():267-299. PubMed ID: 28413031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.